Ranibizumab Biosimilar - Research Grade

Giannos, S.A et al. Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits. Pharm Res, 2024, 41, 1247–1256.

6.91mg/ml

Human IgG1 Kappa

Humanized

Detects human VEGF. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Ranibizumab.

Vascular endothelial growth factor (VEGF) is the principal driver of angiogenesis and a long-standing focus in tumour and ophthalmic research. Our research-grade anti-VEGF antibody is an unconjugated, non-therapeutic analog of ranibizumab that binds human VEGF to support ligand-neutralisation studies. Provided for research use only, it is formulated to a low-endotoxin specification appropriate for in vivo experiments and is produced in scalable milligram to gram quantities for high-throughput and bulk applications. Common uses include angiogenesis assays, VEGF-blockade controls, in vitro screening, and preclinical disease models requiring a consistent, well-characterised reagent.

P15692